Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry
Background: Previous studies and case-series showed improvement in left ventricular (LV) function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We therefore aimed to evaluate whether also right ventricular (RV) function may improve after sacubitril/valsartan therap...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-04-01
|
| Series: | International Journal of Cardiology: Heart & Vasculature |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352906720300622 |
| _version_ | 1828766159432843264 |
|---|---|
| author | Michele Correale Adriana Mallardi Pietro Mazzeo Lucia Tricarico Claudia Diella Valentina Romano Armando Ferraretti Alessandra Leopizzi Giuseppina Merolla Matteo Di Biase Natale Daniele Brunetti |
| author_facet | Michele Correale Adriana Mallardi Pietro Mazzeo Lucia Tricarico Claudia Diella Valentina Romano Armando Ferraretti Alessandra Leopizzi Giuseppina Merolla Matteo Di Biase Natale Daniele Brunetti |
| author_sort | Michele Correale |
| collection | DOAJ |
| description | Background: Previous studies and case-series showed improvement in left ventricular (LV) function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We therefore aimed to evaluate whether also right ventricular (RV) function may improve after sacubitril/valsartan therapy. Methods: Sixty consecutive patients with chronic heart failure and NYHA class II-III were followed up for 12 months after therapy with sacubitril/valsartan. Left and (RV) function was assessed at baseline and after 12 months of therapy. Results: At 12-month control, therapy with sacubitril/valsartan was associated with a significant improvement in a series of echo parameters: LVEF (p < 0.05), LV end-systolic volume (p < 0.01), left atrium area (p < 0.05).Right ventricular echo parameters were also improved after sacubitril/valsartan therapy: PAsP (31.0 ± 12.8 vs 34.7 ± 12.5 mmHg, p < 0.05), TAPSE (17.8 ± 3.9 vs 16.5 ± 4.0 mm, p < 0.001); mean PAsP reduction was 3.7 ± 11.4 mmHg (-6.3 ± 37.7%), mean TAPSE increase 1.3 ± 2.5 mm (+9.5 ± 15.7%).Indexed (%) improvement in PAsP (r 0.33, p < 0.01) and TAPSE (r −0.42, p < 0.01) values were proportional to baseline levels. Improvement in PAsP and TAPSE were independent of left ventricular improvements except for PAsP and end-systolic volumes (r 0.44, p < 0.01). Conclusions: In a real world scenario, sacubitril/valsartan was associated with an improved RV function. Keywords: Sacubitril valsartan, Neprilysin inhibitors, ARNI, Right ventricular function, Chronic heart failure |
| first_indexed | 2024-12-11T07:00:10Z |
| format | Article |
| id | doaj.art-6b7d27beb6644ae69f4a715b92335bb5 |
| institution | Directory Open Access Journal |
| issn | 2352-9067 |
| language | English |
| last_indexed | 2024-12-11T07:00:10Z |
| publishDate | 2020-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Cardiology: Heart & Vasculature |
| spelling | doaj.art-6b7d27beb6644ae69f4a715b92335bb52022-12-22T01:16:38ZengElsevierInternational Journal of Cardiology: Heart & Vasculature2352-90672020-04-0127Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure RegistryMichele Correale0Adriana Mallardi1Pietro Mazzeo2Lucia Tricarico3Claudia Diella4Valentina Romano5Armando Ferraretti6Alessandra Leopizzi7Giuseppina Merolla8Matteo Di Biase9Natale Daniele Brunetti10Ospedali Riuniti University Hospital, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyCardiology Department, Civic Hospital, Canosa di Puglia, BAT, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyOspedali Riuniti University Hospital, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, ItalyDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; Corresponding author.Background: Previous studies and case-series showed improvement in left ventricular (LV) function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We therefore aimed to evaluate whether also right ventricular (RV) function may improve after sacubitril/valsartan therapy. Methods: Sixty consecutive patients with chronic heart failure and NYHA class II-III were followed up for 12 months after therapy with sacubitril/valsartan. Left and (RV) function was assessed at baseline and after 12 months of therapy. Results: At 12-month control, therapy with sacubitril/valsartan was associated with a significant improvement in a series of echo parameters: LVEF (p < 0.05), LV end-systolic volume (p < 0.01), left atrium area (p < 0.05).Right ventricular echo parameters were also improved after sacubitril/valsartan therapy: PAsP (31.0 ± 12.8 vs 34.7 ± 12.5 mmHg, p < 0.05), TAPSE (17.8 ± 3.9 vs 16.5 ± 4.0 mm, p < 0.001); mean PAsP reduction was 3.7 ± 11.4 mmHg (-6.3 ± 37.7%), mean TAPSE increase 1.3 ± 2.5 mm (+9.5 ± 15.7%).Indexed (%) improvement in PAsP (r 0.33, p < 0.01) and TAPSE (r −0.42, p < 0.01) values were proportional to baseline levels. Improvement in PAsP and TAPSE were independent of left ventricular improvements except for PAsP and end-systolic volumes (r 0.44, p < 0.01). Conclusions: In a real world scenario, sacubitril/valsartan was associated with an improved RV function. Keywords: Sacubitril valsartan, Neprilysin inhibitors, ARNI, Right ventricular function, Chronic heart failurehttp://www.sciencedirect.com/science/article/pii/S2352906720300622 |
| spellingShingle | Michele Correale Adriana Mallardi Pietro Mazzeo Lucia Tricarico Claudia Diella Valentina Romano Armando Ferraretti Alessandra Leopizzi Giuseppina Merolla Matteo Di Biase Natale Daniele Brunetti Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry International Journal of Cardiology: Heart & Vasculature |
| title | Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry |
| title_full | Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry |
| title_fullStr | Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry |
| title_full_unstemmed | Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry |
| title_short | Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry |
| title_sort | sacubitril valsartan improves right ventricular function in a real life population of patients with chronic heart failure the daunia heart failure registry |
| url | http://www.sciencedirect.com/science/article/pii/S2352906720300622 |
| work_keys_str_mv | AT michelecorreale sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT adrianamallardi sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT pietromazzeo sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT luciatricarico sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT claudiadiella sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT valentinaromano sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT armandoferraretti sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT alessandraleopizzi sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT giuseppinamerolla sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT matteodibiase sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry AT nataledanielebrunetti sacubitrilvalsartanimprovesrightventricularfunctioninareallifepopulationofpatientswithchronicheartfailurethedauniaheartfailureregistry |